What You Ought to Know:
–Flatiron Well being, a number one healthtech firm devoted to enhancing most cancers care and advancing analysis utilizing real-world information, as we speak introduced the launch of six new hematology Panoramic datasets, representing one other essential second of scientific innovation that foundationally redefines the corporate’s real-world proof choices in blood cancers.
– Flatiron’s Panoramic information unlocks the corporate’s complete affected person community, leveraging breakthrough AI and huge language mannequin capabilities alongside their intensive database to extract and validate scientific information at unprecedented scale.
Flatiron Well being expands hematology analysis capabilities by AI-powered real-world datasets
Flatiron Well being, an impartial affiliate of the Roche Group, is advancing real-world oncology analysis with the discharge of its new hematology Panoramic datasets, encompassing greater than 505,000 affected person information throughout 5 B-cell lymphoma subtypes and a number of myeloma. The datasets are a part of a broader repository of over 5 million most cancers affected person information, representing 1.5 billion information factors that replicate actual scientific follow throughout numerous care settings. Collectively, they goal to remodel how hematologic malignancies are studied, understood, and handled by enabling data-driven insights that mirror sufferers’ real-world experiences.
Developed below Flatiron’s validated information high quality framework, the Panoramic datasets mark a six-fold enhance in cohort measurement in comparison with the corporate’s prior hematology collections. They seize intensive longitudinal particulars together with measurable residual illness (MRD) testing and CAR-T remedy utilization—two key indicators of latest hematology follow. This depth of scientific data permits researchers to look at fashionable therapy patterns, adherence, and outcomes with better precision, supporting the event of personalised therapeutic methods and extra inclusive trial designs.
Chief Government Officer Nathan Hubbard described the datasets as a fruits of Flatiron’s decade-long effort to construct a worldwide oncology proof infrastructure. He famous that combining the corporate’s confirmed AI and machine studying capabilities with scientific rigor permits extra exact, individualized look after sufferers with blood cancers. The brand new datasets additionally enhance interoperability, permitting streamlined analyses throughout associated lymphoma sorts and longitudinal monitoring of illness transformation over time.
Flatiron’s hematology program helps detailed investigations into complicated subgroups similar to high-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements or a number of myeloma instances with high-risk cytogenetics. The information additionally facilitate evaluation of real-world effectiveness, molecular response, and opposed occasions—dimensions that complement proof from conventional scientific trials. By offering built-in perception into inpatient and outpatient care, infusion and oral regimens, and mobile therapies, the datasets create a panoramic view of the affected person journey that was beforehand fragmented.
With greater than 250 publications and 275 upcoming analysis displays throughout international conferences in 2025, Flatiron continues to form the proof requirements of digital oncology. Its participation at ISPOR Europe and ASH 2025 underscores a broader purpose: to responsibly apply synthetic intelligence and real-world proof towards increasing scientific entry to uncommon illness populations, closing persistent information gaps, and accelerating the subsequent technology of hematology innovation.
